Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine
Keywords:
Melanoma
Quality of life
Dabrafenib
Chemotherapy
BRAF
Citation:
Grob, J.J. (Jean-Jacques); Amonkar, M.M. (M. M.); Martin-Algarra, S. (Salvador); et al. "Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine". Annals of Oncology. 25 (7), 2014, 1428 - 1436
Statistics and impact
0 citas en
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.